Clinical Trial Update: Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera [Phase 4]

View source ↗

Summary

A Phase 4 trial update reports a decrease in neuropsychiatric side effects after switching from Atripla to Eviplera in people with HIV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• Eviplera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate)

Snippet

Sponsor: Sheba Medical Center | Conditions: HIV | Phase 4 | Status: TERMINATED